Abstract Liver cancer, particularly hepatocellular carcinoma (HCC), is the third leading cause of cancer death in the world. Bile acids (BAs) are liver-produced amphipathic molecules that are required to facilitate the absorption of cholesterol, fat-soluble vitamins, and lipids in the intestine. However, BAs are also known to act as potential carcinogens and deregulation of BA homeostasis has been linked to HCC formation. Two key BA receptors, farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), were recently identified, which provides great insights into BAs' normal physiological functions as well as their carcinogenic effects. In this review, we focus on the potential links among BAs, two BA receptors, and HCC. FXR and TGR5 not only play key roles in regulating BA homeostasis but also are essential in suppressing BAs' carcinogenic effects on liver cancer.
Introduction
Bile acids (BAs) are a group of water-soluble steroids formed after the catabolism of cholesterol, and synthesized in hepatocytes of the liver [1] . There are two primary BAs, cholic acid (CA) and chenodeoxycholic acid (CDCA). After being dehydroxylated by the intestinal bacteria, these two primary BAs are then transformed into secondary BAs. CA becomes deoxycholic acid (DCA) and CDCA becomes lithocholic acid (LCA). Thereafter, BAs are reabsorbed by the intestine and then circulated back to the liver, where BAs are further conjugated with glycine or taurine. The recycling of BAs from intestine back to liver is known as the enterohepatic circulation [2] .
The levels of BAs must be tightly controlled. Deregulation of BAs leads to several pathological consequences, such as cholestasis and cancer. Since 1940, studies have suggested that BAs could act as potential carcinogens [3] . Abnormally high concentrations of BAs induce cell death and inflammation, thereby promoting cancer development. Due to its high levels in the gastro-intestinal (GI) tract, BAs have been highly linked to the risk of GI cancers, including liver cancer.
Bile Acids and Liver Cancer
Liver cancer, particularly hepatocellular carcinoma (HCC), is the third leading cause of cancer death in the world [4] . Many studies have shed light on the initiation and development of HCC. HCC is usually associated with the chronic inflammation in liver, including the infection of hepatitis B or C virus and non-alcoholic steatohepatitis (NASH) [5] . The liver is the largest organ for metabolism and detoxification. Therefore, both xenobiotics and endobiotics, such as BAs, may induce liver injury. Inside the liver, BAs are useful to promote bile flow and eliminate cholesterol, bilirubin, steroid hormone derivatives, and xenobiotics [6] . However, abnormally high levels of BAs induce hepatocyte DNA damage, which could significantly increase the mutation rate of tumor suppressor genes and oncogenes. Furthermore, BAs can induce cell death and inflammation to promote carcinogenesis. The association of BAs with liver cancer has been demonstrated from both human and animal studies. High levels of BAs in the liver will result in cholestasis and the link between cholestatic liver diseases and liver cancer has been established in clinical studies [7] . Knisely et al. [8 •• ] reports a link between progressive familial intrahepatic cholestasis type 2 and HCC in children who have cholestasis that results in accumulation of BAs in the liver. Mutations in the bile salt export pump, ABCB11, also result in liver tumor formation [9] . These results strongly suggest that BAs may directly contribute to the development of HCC in humans. Moreover, these children are also prone to developing cholangiocarcinoma, an adenocarcinoma that arises from the bile duct epithelium [7] . In rats, the elevated BA concentrations play a role as an endogenous promoter in hepatocarcinogenesis [10] [11] [12] . Similarly, mice with multi-drug resistance 2 (mdr2) gene deletion have accumulation of BAs inside the liver. These mice display progressive inflammation, and then HCC and cholangiocarcinoma [13] . Feeding mice with a CA-enriched diet strongly promoted diethylnitrosamine (DEN)-initiated hepatocarcinogenesis in mice [14 •• ]. Usually, the hydrophobic BAs, such as LCA, induce higher degree of liver injury. Whether there is a correlation between the hydrophobicity of BAs and their capacity to promote liver cancer is still unclear. Also in human, the primary BA species that induce liver cancer need to be identified and verified in the future studies.
In vitro studies show that BAs may directly induce hepatocyte death by ROS-mediated cell apoptosis [15] . Other studies indicate that BAs activate the Fas receptor in a ligand-independent manner, thereby inducing the apoptosis of primary hepatocytes [16, 17] . Interestingly, BAs simultaneously activate certain cell survival pathways, including extracellular signal-regulated kinase (ERK) pathway and AKT pathway, which can suppress cell apoptosis [18] . The phosphorylation of ERK1, ERK2, and AKT is increased after BA treatments. However, the mechanism by which BAs induce those cell protective pathways is still unknown.
It is now clear that, in addition to their important roles in facilitating nutritional absorption, BAs are also signaling molecules that activate BA receptors to regulate gene expression. Two major receptors of BAs have been identified: the nuclear receptor FXR [19, 20] , and TGR5, a G In addition to promoting liver repair, FXR may protect against hepatocarcinogenesis by modulating NF-jB-mediated hepatic inflammatory responses. NF-jB is known to mediate the effect of chronic inflammation on HCC development [13, 42 •• ] . FXR is shown to negatively regulate NF-jB signaling. Overexpression of FXR suppresses the expression of inflammatory mediators in both HepG2 cells and the primary hepatocytes. Moreover, FXR-/-mice showed increased levels of several proinflammatory cytokines in response to lipopolysaccharide (LPS) challenge. Interestingly, FXR activation has no negative effects on NF-jB-activated anti-apoptotic genes, suggesting that FXR may selectively inhibit NF-jB-mediated hepatic inflammatory response but maintains or even enhances the cell survival response [43
Another potential role of FXR in suppressing inflammation may be through the activation of the cytokine inducible SH2-containing protein (CISH). CISH, a therapeutic target for inflammatory diseases, represses cytokine signaling by reducing JAK2/STAT5 activation. FXR upregulates CISH at both transcriptional and translational levels, thereby inhibiting IL-6-induced STAT5 activation [44] .
Based on the results so far, FXR may confer hepatoprotection and suppress HCC at multiple levels ( [49, 50] , which may add another level of protection by FXR as a tumor suppressor. However, the mechanism is still unclear and the conclusion is still controversial as another report has opposite observation that FXR promotes cancer cell proliferation [51] .
FXR-/-mice also offered a unique animal model to better understand human hepatocarcinogenesis. HCC generally develops from sequential pathological changes, which include inflammation, compensatory regeneration, liver matrix alteration, fibrosis and cirrhosis. Studies have shown that FXR expression is decreased in hepatitis C virus-induced liver fibrosis and human HCC samples [52] . Similarly, in human HCC samples, the expression of both FXR and its target gene SHP is significantly decreased [50, 53] . FXR expression can be downregulated by inflammatory cytokines, which are upregulated in HCC microenvironment [53] . Recently, FXR is identified as a target of miR-421 in HCC cells. miR-421 suppresses the translation of FXR protein by targeting the 3 0 -UTR of FXR mRNA [54] . These results suggest that FXR may be one of the downstream targets of chronic inflammation after virus infection or other factors. The functional deficiency of FXR will subsequently result in the disruption of liver metabolic homeostasis, which may constitute a second hit to further exacerbate cell death, inflammation and HCC development.
In summary, in addition to acting as a metabolic regulator, FXR is also critical to protect the liver from cancer development. FXR-/-mice recapitulate many features of human hepatocarcinogenesis. Inflammation downregulates FXR expression, thereby leading to metabolic dysfunction of liver and the development of HCC. In summary, emerging evidence indicates that the membrane BA receptor TGR5 is important to mediate several aspects of BA signaling. TGR5 plays important roles in metabolic regulation and inflammatory response. In addition, TGR5 may also be a potential tumor suppressor in liver cancer.
FXR and TGR5 as Drug Targets
Both FXR and TGR5 are attractive targets for drug development. We have previously summarized the synthetic or natural ligands for FXR and TGR5 [19, 25] . The search for more potent and selective compounds for FXR and TGR5 is still going. Several new FXR ligands are identified and some of FXR ligands are currently under clinical trials already [70] [71] [72] [73] . The screening for new TGR5 ligands are also very active and we expect some of TGR5 ligands will enter clinical trials in the near future [74, 75] . The primary clinical trials are focused on targeting metabolic diseases such as primary biliary cirrhosis (PBC). However, with more studies on the roles of FXR and TGR5 in HCC, the application of their ligands in the prevention or treatment of liver cancer will be the next objective.
Conclusions
The amphiphilic characters of bile acids are required to help nutrition absorption in the small intestines, but also process potential carcinogenic effect. Therefore, BA homeostasis is not only important to help regulate other metabolic pathways associated with the diet input but also is key to prevent carcinogenic effect due to dysregulation of BA metabolism. Two BA receptors, FXR and TGR5, may coordinate each other to maintain levels of BAs and regulate BA-mediated signaling pathways. As noted, FXR and TGR5 are differentially expressed in the liver. FXR is highly expressed in hepatocytes and cholangiocytes. TGR5 is mainly expressed in Kupffer cells. High levels of TGR5 are also detected in gallbladder epithelial cells, gallbladder smooth muscle cells and sinusoidal endothelial cells [27] . Thus the two BA receptors constitute a potent defense mechanism to suppress NF-jB-dependent inflammation and prevent BA-induced malignancy such as HCC (Fig. 1 ).
As such, manipulation of BA signaling pathways mediated by FXR and TGR5 could be considered as novel drug targets for the prevention and treatments of liver cancer. 
